ONVO 250117 7.50P (ONVO250117P7500) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayClose Jan 3 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Stock_Drift

Nov 29, 2024 03:31

Pre Market Ticks. 4:30am 11/29

$Spectral AI (MDAI.US)$ $Onconetix (ONCO.US)$ $Pyxis Oncology (PYXS.US)$ $Rigetti Computing (RGTI.US)$ $Cabaletta Bio (CABA.US)$ $Ocean Power Technologies (OPTT.US)$ $Organovo Holdings (ONVO.US)$ $Alterity Therapeutics (ATHE.US)$ $SOS Ltd (SOS.US)$ $Rectitude Holdings (RECT.US)$ $Lion Group (LGHL.US)$ $Biomerica (BMRA.US)$ $Primega Group (PGHL.US)$
📊⚡️📊

Quantum Computing Boom: The next AI?

Jaguar8

Nov 28, 2024 22:14

🟢My Watchlist Friday (Nov 29). Trade the Chart. No emotions. Be good. Be kind.

Its Friday with shorter trading time. Sleepy already. Some will run and some will get delayed market reaction.
$Applied Therapeutics (APLT.US)$ Crashed after FDA CRL but will resubmit. Dropped from 10 to 1.3 rebounded to 1.95. SI 16%
$PainReform (PRFX.US)$ Microfloat. Up after hours. SI 20%. 0 shares LTB. CTB 436%. If there is no catalyst, microfloats will be a quick play.✔️
$Blue Ocean Acquisition Corp(Delisted) (BOCN.US)$ Merger ...

Quantum Computing Boom: The next AI?

Jaguar8

Nov 20, 2024 07:08

NEWS

$Organovo Holdings (ONVO.US)$
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
Organovo Holdings (NASDAQ:ONVO)presented Phase 2 clinical trial results for FXR314 at The Liver Meeting. The study involved 214 MASH patients randomized to receive 3mg, 6mg FXR314, or placebo. The drug demonstrated statistically significant liver fat reduction from baseline: 22.8% (3mg) and 17.5% (6mg) versus 6.1% placebo. Notably, >30% MRI-PDFF reduction was ac...

Jaguar8

Nov 13, 2024 07:07

NEWS

$Organovo Holdings (ONVO.US)$
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
Organovo Holdings (Nasdaq: ONVO) announces that its lead clinical stage drug, FXR314, will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The presentation, scheduled for November 17, 2024, will be del...

Jaguar8

Jul 16, 2024 08:41

NEWS

$Organovo Holdings (ONVO.US)$
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
Organovo Holdings (Nasdaq: ONVO) presented its outlook and plans at the Jones Trading Healthcare Conference, focusing on FXR314, its treatment for inflammatory bowel disease (IBD). Executive Chairman Keith Murphy highlighted the strong preclinical and human rationale for FXR314 in Phase 2a ulcerative colitis...